RecruitingNot ApplicableNCT06027788

CTSN Embolic Protection Trial

Embolic Protection in Patients Undergoing High-Risk Valve Surgery


Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

842 participants

Start Date

Sep 18, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.


Eligibility

Min Age: 60 Years

Inclusion Criteria10

  • Age ≥ 60 years
  • Planned de novo or redo:
  • Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
  • Mitral valve replacement (MVR) ± CABG
  • Mitral Valve Repair + CABG,
  • Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
  • Valve sparing aortic root replacement (David procedure)
  • Valve sparing aortic root replacement (David procedure)
  • No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization
  • Ability to provide informed consent and comply with the protocol

Exclusion Criteria9

  • History of clinical stroke within 3 months prior to randomization
  • Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
  • Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
  • Active endocarditis at time of randomization with vegetation criteria
  • Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
  • Participation in an interventional (drug or device) trial
  • Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
  • Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
  • Planned concomitant carotid endarterectomy during index surgical procedure

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECardioGard Embolic Protection Cannula

The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.

DEVICEStandard Aortic Cannula

An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.


Locations(28)

CHI St. Vincent Heart Institute

North Little Rock, Arkansas, United States

Keck Hospital of the University of Southern California

Los Angeles, California, United States

Emory University

Atlanta, Georgia, United States

Indiana University

Bloomington, Indiana, United States

Indiana Ohio Heart

Fort Wayne, Indiana, United States

Ochsner Clinic

New Orleans, Louisiana, United States

Maine Medical Center

Portland, Maine, United States

Johns Hopkins Medicine

Baltimore, Maryland, United States

University of Maryland

College Park, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Columbia University Medical Center

New York, New York, United States

New York Presbyterian-Cornell Medical Center

New York, New York, United States

NYU Langone Hospital Brooklyn

New York, New York, United States

Northwell Health

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Duke University

Durham, North Carolina, United States

University Hospitals

Cleveland, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Virginia

Charlottesville, Virginia, United States

West Virginia University

Morgantown, West Virginia, United States

London Health Sciences Centre

London, Ontario, Canada

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Montreal Heart Institute

Montreal, Quebec, Canada

Hôpital Laval

Québec, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06027788


Related Trials